Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis
Allergy · 2026-10 · 81 (10) · 3599-3607
DOI: 10.1111/all.70467 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Allergy, online erschienen am 02.08.2026. Verfasst von Madeline Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Microbiota, Pyrimidines, Skin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is characterized by microbial dysbiosis, notably an overabundance of Staphylococcus species. This study aimed to evaluate the effects of abrocitinib, a Janus kinase 1‐selective inhibitor, on the skin microbiome and clinical outcomes in patients with moderate‐to‐severe AD.
Methods
Patients enrolled in JADE MOA (NCT03915496) were randomly assigned to receive once‐daily abrocitinib (100 or 200 mg) or placebo for 12 weeks. Skin swabs collected at baseline and Weeks 2, 4, and 12 underwent 16S rRNA gene amplicon sequencing to determine microbial composition. Disease severity was assessed at the same time points using established clinical metrics. Associations between microbial abundance and clinical metrics, as well as inflammatory and skin barrier markers, were investigated.
Results
Data from 43 patients were included. Alpha diversity increased significantly at Week 12 of treatment with abrocitinib 200 mg. Beta diversity analysis revealed clustering of the abrocitinib groups away from placebo as early as Week 2; divergence continued through Week 12. Staphylococcus and S. aureus relative abundance decreased in a dose‐dependent manner from Week 2 through Week 12 of abrocitinib treatment. Changes in skin microbial composition corresponded with improvements in clinical metrics of disease severity as well as immune markers of AD.
Conclusions
Abrocitinib treatment is associated with beneficial changes in the skin microbiome, notably a reduction in S. aureus and increased microbial diversity. These findings provide insight into the mechanism of action of abrocitinib and the interplay of immunomodulation and the skin microbiome in AD. Trial Registration ClinicalTrials.gov identifier: NCT03915496
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Pfizer Inc., San Diego, California, USA.
- Pfizer Inc., Groton, Connecticut, USA.
- Pfizer Inc., Istanbul, Turkey.
- Pfizer Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Madeline Kim, Ester Del Duca, Joel Correa Da Rosa, Juliana Pulsinelli, Yeriel Estrada, Emma Guttman-Yassky
Förderung
- Pfizer
Zitieren
APA
Kim, M., Del Duca, E., Correa Da Rosa, J., Pulsinelli, J., Estrada, Y., Xu, D., Chan, G., Chen, A., Güler, E., Page, K., & Guttman-Yassky, E. (2026). Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis. Allergy, 81(10), 3599-3607. https://doi.org/10.1111/all.70467
Vancouver
Kim M, Del Duca E, Correa Da Rosa J, Pulsinelli J, Estrada Y, Xu D, et al. Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis. Allergy. 2026;81(10):3599-3607. doi:10.1111/all.70467
BibTeX
@article{Kim2026,
author = {Kim, Madeline and Del Duca, Ester and Correa Da Rosa, Joel and Pulsinelli, Juliana and Estrada, Yeriel and Xu, Dan and Chan, Gary and Chen, Allshine and Güler, Erman and Page, Karen and Guttman-Yassky, Emma},
title = {Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis},
journal = {Allergy},
year = {2026},
volume = {81},
number = {10},
pages = {3599--3607},
doi = {10.1111/all.70467}
}
EUVIMED